Twist Bioscience and Cancer Research Horizons Enter into Collaboration to Advance Cancer Research
18 Julho 2023 - 9:00AM
Business Wire
Cancer Research Horizons is the innovation arm
of Cancer Research UK
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, and Cancer Research Horizons, the
innovation engine at the core of one of the world’s largest private
funders of cancer research, Cancer Research UK (CRUK), today
announced an agreement under which Cancer Research Horizons will
license the entire Twist Biopharma Solutions Library of
Libraries.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230718140133/en/
“Teaming up with Cancer Research Horizons to support exploratory
drug discovery efforts, validating and de-risking biological
targets has the potential to be groundbreaking for patients,” said
Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
“Cancer Research Horizons acts as a conduit between academia and
industry, with our collaboration enabling early-stage antibody
identification through access to our ‘Library of Libraries.’ With
two mission-driven organizations aligning behind innovative
technology solutions to improve health to make the world a better
place, the opportunity to identify new biotherapeutics offers
tremendous hope to those who need it most.”
“We’re delighted to partner with Twist Bioscience, an exciting
technology platform company who will enhance our antibody discovery
capabilities with their highly diverse phage display libraries,”
said Hamish Ryder, CEO of Therapeutic Innovation at Cancer Research
Horizons. “We look forward to using this technology to accelerate
the delivery of high-quality therapeutics and diagnostics to cancer
patients, in collaboration with our academic and industrial
partners.”
Under the terms of the agreement, Cancer Research Horizons will
license Twist’s Library of Libraries, an expansive collection of
synthesized antibody libraries designed based on naturally
occurring sequences that harness innovative structural and
developability features to cover a wide range of antibody drug
targets, for a period of five years. Twist will receive a library
access fee and will be eligible to receive annual maintenance fees
as well as a share of revenue from any assets sold or
transferred.
About Cancer Research Horizons
Cancer Research Horizons is the innovation arm of Cancer
Research UK – one of the world’s largest charitable funders of
cancer research. We bring together world-leading minds, bold ideas
and the right partners to bridge the gap between research and
introducing new therapeutics into the market. We focus on the
riskier, more profound ideas that can lead to true innovation.
By uniting our commercial partnerships and therapeutic
innovation capabilities, Cancer Research Horizons is uniquely
placed to support translational funding, licensing and
collaboration, spin-out creation, and offer a full spectrum of drug
discovery and clinical capabilities. With access to Cancer Research
UK’s network of 4,000 exceptional researchers, and £300+ million of
annual research spend, we’re a powerful partner in the fight to
conquer cancer. Every penny we make goes back into funding the next
bold steps, to help bring forward the day when all cancers are
conquered. To date, we’ve played an instrumental role in forming
over 60 spin-out companies and helped to bring 11 cancer drugs to
market. For more information and to get in touch with the team,
visit cancerresearchhorizons.com.
About Twist Biopharma Solutions (The Biologics Discovery and
Optimization Division of Twist Bioscience)
Twist Biopharma Solutions combines high-throughput DNA synthesis
technology, deep expertise in antibody engineering and in vivo, in
vitro and in silico discovery methods to provide end-to-end
antibody discovery solutions across the preclinical continuum and
tailored to our partner’s specific needs. By leveraging our unique
ability to manufacture DNA at scale, we can construct proprietary
antibody libraries with discovery beginning with either in vivo or
in vitro diversity. Our Library of Libraries gives our partners an
integral and unbiased resource for antibody therapeutic discovery
and optimization. This precise and rational approach to library
fabrication combined with sophisticated bioinformatics and software
expertise expedites antibody discovery by decreasing risk,
increasing speed, and lowering the failure rate for antibody
therapeutic development. Additionally, in vivo discovery approaches
including single B cell screening and hybridoma discovery enable
parallel paths where multiple technology methods can be leveraged
to create a panel of highly diverse antibody leads. Our automated
screening and panning processes enable us to identify high affinity
leads that our partners can move forward into the clinic. We also
offer supporting development capabilities, including IgG
conversion, expression, purification, biophysical characterization,
and functional characterization.
For more information visit:
https://www.twistbioscience.com/products/antibody-discovery/twist-bioscience-and-abveris
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including statements regarding the potential success of the
collaboration and potential future revenue from any assets sold or
transferred, are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
ability to achieve the expected benefits of Twist Bioscience’s
workforce reduction, transition of production to the Factory of the
Future and reduced investments in DNA data storage; the ability to
attract new customers and retain and grow sales from existing
customers; the ability of Twist to achieve sufficient revenue to
achieve or maintain positive cash flow from operations or
profitability in any given period; risks and uncertainties of
rapidly changing technologies and extensive competition in
synthetic biology that could make the products Twist Bioscience is
developing obsolete or non-competitive; uncertainties of the
retention of significant customers; the ability of Twist Bioscience
to successfully integrate acquired companies and to achieve
expected benefits from acquisitions; supply chain and other
disruptions caused by the COVID-19 pandemic or otherwise; risks of
third party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist Bioscience’s patents or
proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies.
For a description of the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on May 8,
2023 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230718140133/en/
For Twist Bioscience: Angela Bitting SVP, Corporate
Affairs 925- 202-6211 abitting@twistbioscience.com
For Cancer Research Horizons: Tim Bodicoat
tim.bodicoat@cancer.org.uk
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024